Trending...
- SCOPY.ME - Revolutionizes Business Strategy Development with AI-Powered Platform
- More high-priority SIGINT solutions were announced for Krypto1000 SIGINT software
- Duke Energy prepares for winter storm in the Carolinas
Patient-founded nonprofit seeks to stimulate innovative research to improve outcomes for patients with ROS1+ cancers.
SACRAMENTO, Calif. - ncarol.com -- The ROS1ders is pleased to issue their 2024 Request for Application (RFA) to study ROS1-positive (ROS1+) cancer. The RFA is open to investigators who hold a doctorate degree and a faculty appointment at an academic or non-profit research institution anywhere in the world.
"While oral targeted therapies are approved to treat ROS1+ cancer, the drugs don't work for everyone, and they eventually stop working. We are committed to investing in research to improve patient outcomes," says Janet Freeman-Daily, MS, Engr, co-founder and president of The ROS1ders.
The ROS1+ Cancer Innovation Award aims to fund high-risk, high-reward projects focused on ROS1+ cancers. The one-year $75,000 seed grant can be used for pre-clinical, translational, or clinical research.
"Seed grants allow for the generation of initial data to support larger research endeavors," said D. Ross Camidge, MD, PhD, Professor of Medicine/Oncology at the University of Colorado and a member of The ROS1ders Scientific Advisory Board. "While some seeds fail, others grow into mighty trees - they can be the seeds of real breakthroughs."
More on ncarol.com
The award program uses a two-step application process. The deadline for a letter of intent is May 3, 2024. Those invited to submit a full application must provide it by August 4, 2024. For more information, visit https://theros1ders.org/seed-grant-program.
About the ROS1ders
Founded by patients in 2015 and incorporated in 2019, The ROS1ders is the largest global group of patients and family members living with ROS1+ cancer. It seeks to improve outcomes for all ROS1+ cancers through community, education, and research. Membership in their private Facebook group exceeds 1200 people from over 30 countries. The nonprofit is internationally recognized in the oncology and patient advocacy communities as experts in their disease. Its resources include a medically-vetted website and collaboration with international ROS1+ clinicians, researchers and industry. Please visit theros1ders.org to learn more.
More on ncarol.com
About ROS1+ Cancer
"While oral targeted therapies are approved to treat ROS1+ cancer, the drugs don't work for everyone, and they eventually stop working. We are committed to investing in research to improve patient outcomes," says Janet Freeman-Daily, MS, Engr, co-founder and president of The ROS1ders.
The ROS1+ Cancer Innovation Award aims to fund high-risk, high-reward projects focused on ROS1+ cancers. The one-year $75,000 seed grant can be used for pre-clinical, translational, or clinical research.
"Seed grants allow for the generation of initial data to support larger research endeavors," said D. Ross Camidge, MD, PhD, Professor of Medicine/Oncology at the University of Colorado and a member of The ROS1ders Scientific Advisory Board. "While some seeds fail, others grow into mighty trees - they can be the seeds of real breakthroughs."
More on ncarol.com
- InventHelp Inventor Develops Specially Designed Cleaning Glove (CNC-1023)
- Foresight Practitioner Conference 2025 – Dates, Venue, Speakers, And Competition Finalists Announced
- Latest Updates to Pennsylvania Medical Malpractice and Birth Injury Law
- Best Plant Varieties for Windbreaks and Shelterbelts
- Celebrating 9 Months of Growth: Jantize America's Raleigh Franchises Thrive Under Local Leadership
The award program uses a two-step application process. The deadline for a letter of intent is May 3, 2024. Those invited to submit a full application must provide it by August 4, 2024. For more information, visit https://theros1ders.org/seed-grant-program.
About the ROS1ders
Founded by patients in 2015 and incorporated in 2019, The ROS1ders is the largest global group of patients and family members living with ROS1+ cancer. It seeks to improve outcomes for all ROS1+ cancers through community, education, and research. Membership in their private Facebook group exceeds 1200 people from over 30 countries. The nonprofit is internationally recognized in the oncology and patient advocacy communities as experts in their disease. Its resources include a medically-vetted website and collaboration with international ROS1+ clinicians, researchers and industry. Please visit theros1ders.org to learn more.
More on ncarol.com
- Genuine Hospitality, LLC Expands Leadership Team with Key Appointments
- New-and-Improved Caribbean-Food Website Dishes Out Free Ground-Shipping Offer; Affiliate Program Garnished with Generous Commission
- 50th Mount Dora Arts Festival set for Feb 1 and 2, 2024
- CCHR Cites Newly Released Mind Control Records to Oppose Psychedelics
- K2 Integrity Appoints Markus Schulz as Chief Technology Officer
About ROS1+ Cancer
- ROS1+ cancer is relatively rare, occurring in just 1-2% of non-small cell lung cancer (NSCLC). The incidence is thought to be similar in other types of cancer.
- Biomarker testing for ROS1 fusions is recommended in guidelines for non-small cell lung cancer (NSCLC), but for few other cancers.
- Patients are typically younger than the average NSCLC patient, have adenocarcinoma, and have no smoking history (a smoking history should not exclude patients from biomarker testing or targeted therapies).
- Oral targeted therapies are the recommended first-line treatment for metastatic ROS1+NSCLC and have increased the survival of patients by years. However, these drugs eventually stop working due to acquired resistance. The mechanisms of resistance are not well understood.
Source: The ROS1ders, Inc.
0 Comments
Latest on ncarol.com
- Benchmark International Facilitated the Transaction BTGunboat International and Grand Large Yachting
- Transform Warehouse Operations: Redefining Logistics with Customized Solutions
- Rebuilding Broken Places and Wayne Community College Culinary Class Partnership
- NaturismRE Introduces Global Accreditation Standards to Redefine Nudist and Naturist Venues
- Enhancing Campus Safety for Women: The Blue Luna's New Initiative
- More high-priority SIGINT solutions were announced for Krypto1000 SIGINT software
- SCOPY.ME - Revolutionizes Business Strategy Development with AI-Powered Platform
- Duke Energy prepares for winter storm in the Carolinas
- TimelyBill to Showcase Innovation at ITEXPO
- Moonshot Announces 6th Annual 2025 Rural Arizona Pitch Competition Tour with Bilingual Resources and Mentors
- The Dental Specialists in Newton, MA, Introduces Cutting-Edge 3Shape TRIOS 5 Intraoral Scanner
- Pikmykid Acquires Visitu to Enhance School Visitor Management Solutions
- Project EverGreen's SnowCare for Troops Program Helps Military Families Weather the Winter During Awareness Month in January
- Modern Dental of Kernersville: Your Trusted Dentist in Kernersville, North Carolina
- Celebrate Love in Style: Introducing the Signature Summer Bundle for 2025 Weddings
- Mattamy Homes: Six-time Best Place to Work winner in Charlotte, NC
- MileMark Explains Latest ABA Rules On Attorney Advertising
- Signs in the Heavens: Prophecy, Eclipses, & Watching for Jesus' Return on Spotify
- The Annual Kingdom Day Parade Celebrates 40th Anniversary With Its " 40th Annual Kingdom Day Parade"
- Morningscore Secures $700k in Funding to Build the Next Generation of AI SEO and Expand Globally